tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Denys-Drash Syndrome D030321 1 associated lipids
Hypophosphatemia D017674 1 associated lipids
Moyamoya Disease D009072 1 associated lipids
Latent Tuberculosis D055985 1 associated lipids
Leukoplakia D007971 1 associated lipids
Oculomotor Nerve Diseases D015840 1 associated lipids
Scorpion Stings D065008 1 associated lipids
Esophageal Perforation D004939 1 associated lipids
Mediastinitis D008480 2 associated lipids
Coproporphyria, Hereditary D046349 1 associated lipids
Ileus D045823 3 associated lipids
Rectal Diseases D012002 1 associated lipids
Angiolymphoid Hyperplasia with Eosinophilia D000796 1 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Undre NA and Schäfer A Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European Tacrolimus Multicentre Renal Study Group. 1998 Transplant. Proc. pmid:9636512
Thomson AW Interspecies comparison of the immunosuppressive efficacy and safety of FK 506. 1990 Transplant. Proc. pmid:1689883
Smoter P et al. Risk factors of acute renal failure after orthotopic liver transplantation: single-center experience. 2014 Transplant. Proc. pmid:25380918
Sewing KF Pharmacokinetics, dosing principles, and blood level monitoring of FK506. 1994 Transplant. Proc. pmid:7527962
Youhua Z et al. Clinical study of FK 506 in renal transplant recipients. 2000 Transplant. Proc. pmid:11119900
Klintmalm GB et al. Prognostic factors for successful conversion from cyclosporine to FK 506-based immunosuppressive therapy for refractory rejection after liver transplantation. US Multicenter FK 506 Liver Study Group. 1993 Transplant. Proc. pmid:7679828
Venkataramanan R et al. Pharmacokinetics of FK 506 in transplant patients. 1991 Transplant. Proc. pmid:1721261
Washburn WK et al. Tacrolimus rescue therapy for renal allograft rejection refractory to cyclosporine-based immunosuppression. 1996 Transplant. Proc. pmid:8623214
Sugioka A et al. FK 506 inhibits tolerance induction in mice liver transplantation. 2005 Jan-Feb Transplant. Proc. pmid:15808576
Brook NR et al. Prograf produces a molecular environment favoring antifibrosis, an effect reversed by the addition of rapamune. 2005 Jan-Feb Transplant. Proc. pmid:15808577
Shitrit D et al. Tacrolimus-induced hemolytic uremic syndrome case presentation in a lung transplant recipient. 2003 Transplant. Proc. pmid:12644073
Crespo-Leiro MG et al. Replacement of cyclosporine by tacrolimus for immunosuppression in heart transplant patients: safety and efficacy. 2002 Transplant. Proc. pmid:11959213
Ringe B et al. Tacrolimus and mycophenolate mofetil in clinical liver transplantation: experience with a steroid-sparing concept. 1998 Transplant. Proc. pmid:9636573
Tashiro H et al. Donor bone marrow perioperatively administered via portal vein induced prolongation of skin allograft survival and microchimerism in liver-transplanted rats. 2000 Transplant. Proc. pmid:11120201
Torio A et al. Effect of CYP3A51/3 polymorphism on blood pressure in renal transplant recipients. 2012 Transplant. Proc. pmid:23146466
Akselband Y et al. Rapamycin inhibits spontaneous and fibroblast growth factor beta-stimulated proliferation of endothelial cells and fibroblasts. 1991 Transplant. Proc. pmid:1721292
Jurewicz WA Immunological and nonimmunological risk factors with tacrolimus and Neoral in renal transplant recipients: an interim report. 1999 Transplant. Proc. pmid:10576048
Kim SJ et al. Randomized trial of tacrolimus versus cyclosporine in steroid withdrawal in living donor renal transplant recipients. 2004 Transplant. Proc. pmid:15518759
Schreiber SL et al. Immunophilin-ligand complexes as probes of intracellular signaling pathways. 1991 Transplant. Proc. pmid:1721293
Klintmalm GB Clinical use of FK 506 in liver transplantation. 1996 Transplant. Proc. pmid:8623484
Boran M et al. Determining renal resistive and pulsatility indexes long-term after kidney transplantation in kidney transplant recipients on cyclosporine a-, tacrolimus-, or sirolimus-based regimens. 2014 Transplant. Proc. pmid:24935296
Butt TR et al. Molecular basis of immunosuppressive drug action: regulation of steroid receptor-mediated transcription by FK 506. 1996 Transplant. Proc. pmid:8623486
Burg M et al. Enteric-coated mycophenolate sodium reduces gastrointestinal symptoms in renal transplant patients. 2009 Transplant. Proc. pmid:20005359
Schneeberger H et al. Tacrolimus as a primary immunosuppressive therapy in cadaveric renal transplantation: five years' experience at a single center. 1998 Transplant. Proc. pmid:9636642
Yamazaki R et al. Interindividual variation of maximal blood levels of tacrolimus after its oral administration in hematopoietic cell transplant recipients. 2009 Transplant. Proc. pmid:19545738
Dammeijer PF et al. Combined effect of low-dose FK 506 and cyclosporine A on skin graft survival. 1990 Transplant. Proc. pmid:1697116
Imai K et al. Pancreaticoduodenal allotransplantation with the use of FK 506, cyclosporine, and triple-regimen immunosuppression. 1990 Transplant. Proc. pmid:1697117
Laftavi MR et al. African American renal transplant recipients (RTR) require higher tacrolimus doses to achieve target levels compared to white RTR: does clotrimazole help? 2013 Transplant. Proc. pmid:24314941
Gavlik A et al. Mycophenolate mofetil rescue therapy in liver transplant recipients: an extended follow-up. 1997 Transplant. Proc. pmid:9365633
Spada M et al. Morphology of acute rejection and observation of lymphoproliferative hyperplastic reaction in FK 506 treated pigs after small bowel transplantation. 1994 Transplant. Proc. pmid:7518142
Foroncewicz B et al. Anti-CD25 and tacrolimus therapy may not prevent early primary biliary cirrhosis recurrence after liver transplantation: two case reports. 2003 Transplant. Proc. pmid:14529924
Reggiani P et al. A "steroid-free" tacrolimus and low-dose mycophenolate mofetil primary immunosuppression does not prevent early acute rejection after liver transplantation. 2005 Transplant. Proc. pmid:15919435
Ushigome H et al. Pediatric living-related renal transplantation under tacrolimus as the primary immunosuppressive agent. 2003 Transplant. Proc. pmid:12591350
Kai N et al. A study on the timing of immunologic priming in autoimmune insulitis in NOD mice. 1992 Transplant. Proc. pmid:1376511
Langrehr JM et al. Liver transplantation in hepatitis B surface antigen positive patients with postoperative long-term immunoprophylaxis. 1995 Transplant. Proc. pmid:7533373
Kim SW et al. Decreased formation of nitric oxide in rats treated with FK506. 2003 Transplant. Proc. pmid:12591357
Huang CT et al. Higher Variability of Tacrolimus Trough Level Increases Risk of Acute Rejection in Kidney Transplant Recipients. Transplant. Proc. pmid:27569931
Nakata S et al. Immunosuppressive effect of FK 506 on cytotoxic T lymphocytes and delayed-type hypersensitivity in rats. 1991 Transplant. Proc. pmid:1721325
Ge J et al. Impact of FOXP3 Polymorphisms on the Blood Level of Tacrolimus in Renal Transplant Recipients. Transplant. Proc. pmid:27569929
Kapturczak MH et al. Pharmacology of calcineurin antagonists. 2004 Transplant. Proc. pmid:15041303
Yang SS et al. A single center, open-label, randomized pilot study to evaluate the safety and efficacy of tacrolimus modified release, Advagraf, versus tacrolimus twice daily, Prograf, in stable renal recipients (single). 2015 Transplant. Proc. pmid:25891697
Hranjec T et al. Benign transient hyperphosphatasemia associated with Epstein-Barr virus enteritis in a pediatric liver transplant patient: a case report. 2008 Transplant. Proc. pmid:18589195
Daly I et al. Mycophenolate mofetil for treatment of chronic rejection in liver allograft under tacrolimus. 2002 Transplant. Proc. pmid:12176458
Jonas S et al. Cyclosporine-based quadruple induction therapy versus tacrolimus-based dual immunosuppression after liver transplantation: ten-year follow-up. 2002 Transplant. Proc. pmid:12176459
Tsuchida Y et al. Vascularized bone marrow allotransplantation in rats prolongs a simultaneous skin allograft. 1997 Transplant. Proc. pmid:9142252
Zegarska J et al. Tacrolimus Metabolite M-III May Have Nephrotoxic and Myelotoxic Effects and Increase the Incidence of Infections in Kidney Transplant Recipients. 2016 Transplant. Proc. pmid:27496443
Fontana I et al. Severe rhabdomyolysis and acute renal failure in a kidney transplant patient treated with tacrolimus and chimaeric CD25 monoclonal antibody. 2004 Transplant. Proc. pmid:15110640
Woodside KJ et al. Conversion from cyclosporine to tacrolimus results in improved creatinine but does not alter lipid profile. 2005 Transplant. Proc. pmid:15919491
Winkler M et al. Comparison of plasma vs whole blood as matrix for FK 506 drug level monitoring. 1995 Transplant. Proc. pmid:7533433
Van Thiel DH et al. Interferon therapy of hepatitis following liver transplantation under FK 506 or cyclosporine. 1991 Transplant. Proc. pmid:1721357
Dahmen U et al. Onset of liver regeneration after subtotal resection is inhibited by the use of new immunosuppressive drugs. 2002 Transplant. Proc. pmid:12270412
Takahara S et al. Excellent results following 3 years of tacrolimus immunosuppression in kidney transplantation recipients in Japan: overall analysis of more than 1000 patients. 2002 Transplant. Proc. pmid:12176500
Boggi U et al. Neoral versus prograf in simultaneous pancreas-kidney transplantation with portal venous drainage: three-year results of a single-center, open-label, prospective, randomized pilot study. 2005 Jul-Aug Transplant. Proc. pmid:16182772
Ribes D et al. Combined use of tacrolimus and sirolimus in de novo renal transplant patients: current data. 2005 Jul-Aug Transplant. Proc. pmid:16182816
Lo CM et al. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong. 1998 Transplant. Proc. pmid:9838571
Reichenspurner H et al. Tacrolimus-based immunosuppressive protocols in lung transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083062
Khanna A et al. Cardiac changes at autopsy in adult liver transplant recipients under tacrolimus. 1997 Feb-Mar Transplant. Proc. pmid:9123118
Alper G and Small SL Cerebrospinal fluid after organ transplantation. 1996 Transplant. Proc. pmid:8908142
Sanghvi A et al. Increased cyclosporine uptake by cells pretreated with FK506 and evidence for binding of both drugs to a common intracellular protein. 1989 Transplant. Proc. pmid:2468204
Winkler M et al. Association of elevated FK 506 plasma levels with nephrotoxicity in liver-grafted patients. 1991 Transplant. Proc. pmid:1721389
Takagishi K et al. Effects of FK-506 on collagen arthritis in mice. 1989 Transplant. Proc. pmid:2468205
Schmidt RJ et al. Hemolytic-uremic syndrome in a renal transplant recipient on FK 506 immunosuppression. 1991 Transplant. Proc. pmid:1721390
Arita C et al. Effect of FK 506 (FR 900506) on collagen arthritis in rats: a preliminary report. 1989 Transplant. Proc. pmid:2468206
Tze WJ et al. Effect of FK 506 on glucose metabolism and insulin secretion in normal rats. 1991 Transplant. Proc. pmid:1721391
Cho JH et al. Impact of cytochrome P450 3A and ATP-binding cassette subfamily B member 1 polymorphisms on tacrolimus dose-adjusted trough concentrations among Korean renal transplant recipients. 2012 Transplant. Proc. pmid:22310591
Ierardi E et al. Long-term tacrolimus: a promising therapeutic approach for Crohn's disease. 2001 Transplant. Proc. pmid:11377467
Jørgensen KA et al. Two-hour blood tacrolimus levels are not superior to trough levels as estimates of the area under the curve in tacrolimus-treated renal transplant patients. 2002 Transplant. Proc. pmid:12176551
Castel MA et al. Primary immunosuppression and outcome differences after heart transplantation: tacrolimus versus cyclosporine. 2011 Jul-Aug Transplant. Proc. pmid:21839245
Ji SM et al. Conversion from cyclosporine to tacrolimus for chronic allograft nephropathy. 2007 Transplant. Proc. pmid:17580148
Mor E et al. Homocysteine levels among transplant recipients: effect of immunosuppressive protocols. 2001 Transplant. Proc. pmid:11543802
Kokado Y et al. Low-dose tacrolimus (FK 506)-based immunosuppressive protocol in living donor renal transplantation. 1999 Feb-Mar Transplant. Proc. pmid:10083515
Falconer SJ et al. Conversion from twice-daily to once-daily tacrolimus in simultaneous pancreas-kidney transplant patients. 2014 Transplant. Proc. pmid:24935313
Matsumiya G et al. Serum interleukin-6 level after cardiac xenotransplantation in primates. 1997 Feb-Mar Transplant. Proc. pmid:9123586
Meloni F et al. Monocyte chemoattractant protein-1 levels in bronchoalveolar lavage fluid of lung-transplanted patients treated with tacrolimus as rescue treatment for refractory acute rejection. 2003 Transplant. Proc. pmid:12826211
Boggs S et al. FK 506 has no short-term effects on endogenous or exogenous myeloid reconstitution in irradiated mice. 1991 Transplant. Proc. pmid:1721420
Ogawa N et al. Suppressive effects of combination therapy with mizoribine and FK 506 on the development of accelerated coronary artery disease and myocardial rejection after heart transplantation. 1996 Transplant. Proc. pmid:8658710
Soran A et al. Renal retransplantation in elderly recipients under tacrolimus-based immunosuppression. 2000 Transplant. Proc. pmid:10812157
Kamar N et al. Efficacy and safety of induction therapy with rabbit antithymocyte globulins in liver transplantation for hepatitis C. 2004 Transplant. Proc. pmid:15621141
Formica RN et al. Sirolimus-based immunosuppression with reduce dose cyclosporine or tacrolimus after renal transplantation. 2003 Transplant. Proc. pmid:12742475
Baran DA et al. Can initial tacrolimus trough levels be predicted from clinical variables? 2004 Transplant. Proc. pmid:15621157
Hasegawa A et al. Optimal use of tacrolimus in living donor renal transplantation in children. 2002 Transplant. Proc. pmid:12176635
El-Safa EA et al. Paradoxical response to tacrolimus assessed by interleukin-2 gene expression. 2006 Transplant. Proc. pmid:17175263
Moura Neto A et al. Frequency of Thyroid Dysfunction in Patients With Diabetes Mellitus Before and After Liver Transplantation. 2018 Transplant. Proc. pmid:29661439
van den Berg AP et al. Prediction of the inhibition of IL-2 production by calcineurin inhibitors. 2001 Feb-Mar Transplant. Proc. pmid:11267197
Kohnle M et al. Conversion to tacrolimus in cyclosporin A treated patients with gum hyperplasia. 1998 Transplant. Proc. pmid:9723413
Alessiani M et al. Effect of perioperative donor bone marrow infusion after small bowel transplantation in swine: preliminary results. 1998 Transplant. Proc. pmid:9745496
Otto C et al. Selective immunosuppression with FK 506, anti-IL-2R, and anti-ICAM-1 monoclonal antibodies: contrasting effects after liver and small bowel transplantation in rats. 1998 Transplant. Proc. pmid:9723426
Chen H et al. Combined effect of rapamycin and FK 506 in prolongation of small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9745497
Ott R et al. Does conversion of immunosuppressive monotherapy from cyclosporine A to tacrolimus improve bone mineral density in long-term stable liver transplant recipients? 2003 Transplant. Proc. pmid:14697971
Demir T et al. Cancer Screening of Renal Transplant Patients Undergoing Long-Term Immunosuppressive Therapy. 2015 Transplant. Proc. pmid:26093731
Thomson AW et al. Influence of FK 506 on T lymphocytes, Langerhans' cells and the expression of cytokine receptors and adhesion molecules in psoriatic skin lesions: a preliminary study. 1991 Transplant. Proc. pmid:1721452
Mohsin N et al. Low tacrolimus dose requirements in renal transplant recipients in the omani population: implications for pharmacogenetics? 2005 Transplant. Proc. pmid:16213259
Todo S et al. Effect of FK506 in experimental organ transplantation. 1988 Transplant. Proc. pmid:2450416
Treede H et al. Incidence and spectrum of infections in lung transplanted patients: comparison of four different immunosuppressive protocols. 2001 Feb-Mar Transplant. Proc. pmid:11267444
Lee CM et al. Monotherapy with tacrolimus for heart and liver transplant: a case report. 2014 Transplant. Proc. pmid:24767396
Chen H et al. FK 506 and rapamycin in combination are not antagonistic but produce extended small bowel graft survival in the mouse. 1998 Transplant. Proc. pmid:9636419
Calne RY Immunosuppression for organ grafting. 1991 Transplant. Proc. pmid:1714646
Yoshimura R et al. A comparative study between cyclosporine and FK 506 effects on renal microsomal P-450. 1991 Transplant. Proc. pmid:1703686
Lawen J et al. Sirolimus and low-dose tacrolimus with antibody induction in kidney transplantation: preliminary results of a pilot study. 2001 Nov-Dec Transplant. Proc. pmid:11750382
Hartwig T et al. Low-dose sirolimus and tacrolimus in kidney transplantation: first results of a single-center experience. 2001 Nov-Dec Transplant. Proc. pmid:11750383